1 / 30

PRIMARY & SECONDARY ANTIBODY DEFICIENCY

PRIMARY & SECONDARY ANTIBODY DEFICIENCY. ANTIBODIES & IMMUNOGLOBULINS. PRIMARY ANTIBODY DEFICIENCY. The European internet-based patient and research database for primary immunodeficiencies: results 2006-2008. Gathman et al ., Clin Exp Immunol (2009); 157 Suppl 1: 3-11.

teva
Télécharger la présentation

PRIMARY & SECONDARY ANTIBODY DEFICIENCY

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. PRIMARY & SECONDARY ANTIBODY DEFICIENCY

  2. ANTIBODIES&IMMUNOGLOBULINS

  3. PRIMARY ANTIBODY DEFICIENCY The European internet-based patient and research database for primary immunodeficiencies: results 2006-2008. Gathman et al., Clin Exp Immunol (2009); 157 Suppl 1: 3-11.

  4. Brit Med J (1989); 298: 516-7

  5. THERAPEUTIC IMMUNOGLOBULIN 1970s - IMIg 1980s - IVIg 1990s - IVIg, SCIg 2000s- product safety - infusion rates / concentration - immunoglobulin retrieval

  6. REPLACEMENT THERAPY

  7. TREATMENT OUTCOMES Wood et al. Clin Exp Immunol (2007); 149: 410-423

  8. EFFICACY & ADVERSITY Immunoglobulin Excipients Soluble CD4/ CD8/ HLA Cytokines Clin Exp Immunol (2004); 136: 111-3

  9. IVIg & SCIg ESID Register 2009

  10. HOME THERAPY

  11. 2008 and 2011

  12. SAME OLD SAME OLD Core of PID management No alternatives Lifelong requirement (usually) Effective (bacterial infection, antibiotic usage, QoL, hospitalisation, life expectancy) Dose requirement  in: - frequent breakthrough infections - chronic inflammation / tissue damage - poor prognosis disease variants

  13. WHAT’S NEW? The three Rs: Reorganisation Reclassification Aarrrgh - ongoing uncertainties over dosing / target levels

  14. DOSE? Impact of trough IgG on pneumonia incidence in primary immunodeficiency: A meta-analysis of clinical studies. Orange JS et al. Clinical Immunology (2010); 137: 21-30

  15. DOSE: INDIVIDUALISATION ‘The goal of replacement therapy should be to improve clinical outcome and not to reach a particular IgG trough level.’ J Allergy Clin Immunol (2010);125:1354-60

  16. DOSE: INDIVIDUALISATION ‘….individualizing the dosage….is preferable to using mean pharmacokinetic parameters.’ Clin Immunol (2011);139:133-41

  17. RECLASSIFICATION Specific Antibody Deficiency  Kawasaki Disease  ‘Other’ Section

  18. REORGANISATION

  19. PRIMARY ANTIBODY DEFICIENCY DISORDERS

  20. SPECIFIC DISORDERS Thymoma with immunodeficiency (Good’s Syndrome) Combined immunodeficiencies requiring haemopoietic stem cell transplantation (HSCT) Specific antibody deficiency (SAD) Transient hypogammaglobulinaemia of infancy (THI)

  21. SPECIFIC DISORDERS (GRADE C, LEVEL III)

  22. SUMMARY: PID

  23. SECONDARY ANTIBODY DEFICIENCY Malignant disease Drugs Protein-losing states Infection (cause & effect) Systemic disease Iatrogenic causes Chromosomal abnormalities

  24. WHAT’S NEW? Secondary Antibody Deficiency  Revision / collation into a single indication + review outcomes (infection / hospitalisation) + dosing (minimum IgG trough 6 g/L)

  25. RECOMMENDATIONS Irreversible hypo- Hypo- associated with CLL/NHL/MM etc. and

  26. GUIDELINES ‘Systematically developed statements to assist practitioner and patient decisions about appropriate health care for specific clinical circumstances’ Evidence-based use Consistency of care Access to safe, high quality products Security of supply Utilising scarce resource

  27. OUTCOMES COMPLICATIONS PROGRESSION OF COMPLICATIONS QUALITY OF LIFE WORKING CAPACITY LIFE EXPECTANCY OPTIMISED GROWTH / DEVELOPMENT

More Related